Status: Recruiting
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
This is a global, randomised, Phase III, multicentre, open-label study evaluating the efficacy, safety and the degree of added benefit of the Surovatamig (AZD0486) plus rituximab combination compared to Investigator's choice of 3 standard immunochemotherapy regimen, conducted in participants with untreated FL.
Participants needed: 1,018
Trial details
Phase: Phase 3Age: 18-130Biological sex: AllType: InterventionalSponsor: AstraZenecaUpdated: Aug 19, 2026Locations: 228
Eligibility criteria
Participant must be at least 18 years of age, inclusive, at the time of signing... [+7]
Follicular large B-cell lymphoma (WHO 2022 classification), formerly Follicular... [+6]